| Literature DB >> 34222052 |
María Gabriela Libisch1, Natalia Rego2, Carlos Robello1,3.
Abstract
Chagas Disease, caused by the protozoan parasite Trypanosoma cruzi, affects nearly eight million people in the world. T. cruzi is a complex taxon represented by different strains with particular characteristics, and it has the ability to infect and interact with almost any nucleated cell. The T. cruzi-host cell interactions will trigger molecular signaling cascades in the host cell that will depend on the particular cell type and T. cruzi strain, and also on many different experimental variables. In this review we collect data from multiple transcriptomic and functional studies performed in different infection models, in order to highlight key differences between works that in our opinion should be addressed when comparing and discussing results. In particular, we focus on changes in the respiratory chain and oxidative phosphorylation of host cells in response to infection, which depends on the experimental model of T. cruzi infection. Finally, we also discuss host cell responses which reiterate independently of the strain, cell type and experimental conditions.Entities:
Keywords: Chagas cardiomyopathy; Chagas disease; Trypanosoma cruzi; experimental variables; host-pathogen; respiratory chain; transcriptomics
Year: 2021 PMID: 34222052 PMCID: PMC8248493 DOI: 10.3389/fcimb.2021.692134
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
Figure 1Experimental variables that impact on T. cruzi – host cell interaction studies.
Different T. cruzi-host cell interaction studies incorporating transcriptomics of the infected host cell.
| N | Strain/DTU | PM | Infection Model | MOI | IT | AT | Methodology | Reference, year |
|---|---|---|---|---|---|---|---|---|
| 1 | Sylvio/TcI | C2C12 | Male mouse C3H/HeN (6-8 weeks) | 106/mice | NA | 3, 37 y 110dpi | Microarrays (Clontech) | ( |
| 2 | ND | NA | Heart Tissues from CCC or DCM patients | NA | NA | NA | Microarrays (Affymetrix) | ( |
| 3 | Tulahuen/TcII |
| Murine fibroblast cell line NIH3T3 | 1:1 | 0 | 8dpi (epis at 37°C) | Microarrays (Custom) | ( |
| 4 | Brazil/TcI Y/TcII | ND | Male Mice CD-1 | 104/mice | NA | 30, 60, 90, 120, 150, 180dpi | Microarrays (Custom) | ( |
| 5 | Tulahuen/TcII | ND | HeLa | 10:1 | 60h | 12hpi | Microarrays (Affymetrix) | ( |
| 6 | Y/TcII | LLCMK2 | Fibroblasts, endothelial and smooth muscle human cells | 30:1 | 2h | 24hpi | Microarrays (Affymetrix) | ( |
| 7 | Brazil/TcI | L6E9 | Cardiomyocytes from neonatal mice (C57BL/6) | 5:1 | 24h | 48hpi | Microarrays (Custom) | ( |
| 8 | Y/TcII | LLCMK2 | Skin from site of infection of BALB/c mice | 106/mice | NA | 24hpi | Microarrays (Affymetrix) | ( |
| 9 | Brazil/TcI Y/TcII CLBr/TcVI Tulahuen/TcII | L6E9 | L6E9, rat myoblast | 1:1 | 48h | 72hpi | Microarrays (Custom) | ( |
| 10 | Tulahuen/TcII | Rat Heart myoblast | Primary human coronary artery smooth muscle | 10:1 | 0 | 30, 60, 120, or 180min | Microarrays (Custom) | ( |
| 11 | Colombiana/TcI | LLCMK2 | C57BL/6 male and female mice | ND | NA | 8 month | Microarrays (Custom) | ( |
| 12 | Dm28c/TcI | Vero | Primary mouse cardiomyocytes obtained from 18-day-old embryos | 10:1 | 6h | 1, 2, 4, 6, 12, 24, and 48hpi | Microarrays (Affymetrix) | ( |
| 13 | Tulahuen/TcII | L6E9 | Primary endothelial cells (EC) from the epididymal fat from rats | 2:1 | 0 | 2, 18, 48hpi | Microarrays (Affymetrix) | ( |
| 14 | Y/TcII | LLCMK2 | 6-8 wk C57BL/6 mice | 103/mice | NA | 18dpi | Microarrays (Affymetrix) | ( |
| 15 | Tulahuen/TcII | LLCMK2 | HeLa | 5:1 | 2h | 18 y 72hpi | Genome wide RNAi. | ( |
| 16 | Dm28c/TcI | Vero | HeLa | 10:1 | 4h | 0, 3, 6hpi | Microarrays (Agilent) | ( |
| 17 | Tulahuen/TcII | Rat Heart myoblast | Human Primary cardiomyocytes | 10:1 | 0 | 15, 30, 60, 90 and 120 min | Microarrays (Affymetrix) | ( |
| 18 | Y/TcII | LLCMK2 | Human foreskin fibroblasts | ND | 2h | 4,6,12,24,48 y 72hpi | Sequencing (Illumina) | ( |
| 19 | Sylvio/TcI Y/TcII | Vero | Human foreskin fibroblasts | 10:1 | 2h | 4, 12, 20, 24, 30, 48, 72 and 96hpi | Sequencing (Illumina) | ( |
| 20 | CLBr/TcVI CL14/TcVI | LLCMK2 | Human foreskin fibroblasts | 80:1 | 2h | 60-96hpi | Sequencing (Illumina) | ( |
| 21 | NA | NA | Blood samples from CCC patients. | NA | NA | NA | Microarrays (Illumina) | ( |
| 22 | NA | NA | Heart biopsies from CCC patients. | NA | NA | NA | Microarrays (Agilent) | ( |
| 23 | NA | NA | Human placental RNA samples from CCC patients | NA | NA | NA | Sequencing (Illumina) | ( |
| 24 | Y/TcII | Vero | Explants of human placenta | 105-106/ml | 0 | 2 or 24hpi | Microarrays (Agilent) | ( |
| 25 | Dm28c/TcI | Vero | Human Primary cardiomyocytes | 10:1 | 2h | 0, 2, 4, 6,12hpi | Microarrays (Agilent) | ( |
| 26 | ND Y/TcII | NA LLCMK2 | CCC and DCM patients C57BL/6 6-8 weeks | NA 103/mice | NA NA | NA 18dpi | Microarrays (Agilent) | ( |
| 27 | Col1.7G2/TcIJG/TcII | SWISS mice | 6-8-week-old male BALB/c mice | 50 | NA | 15dpi | Sequencing (Illumina) | ( |
| 28 | Brazil/TcI Y/TcII CLBr/TcVI Tulahuen/TcII | L6E9 | L6E9 | 1:1 | 48h | 72hpi | Microarrays (Custom) | ( |
| 29 | CLBr/TcVI CL14/TcVI | LLCMK2 | Human foreskin fibroblasts | 80:1 | 2h | 60 and 96hpi for infected samples. 48 and 60hpi for controls | Sequencing (Illumina) | ( |
PM, Parasite Propagation Model; MOI, Multiplicity of Infection; IT, Interaction Time; AT, Analyzed Time; NA, Not Applicable; ND, No Data available; C2C12, mice myoblast cells; LLCMK2, Kidney cells from Macaca mulatta; Vero, Kidney cells from Cercopithecus aethiops; L6E9, myoblast Rat cells.
Transcriptomic and functional results from different studies related to the host cell respiration response to T. cruzi infection.
| N | Strain/DTU | PM | Infection model | MOI | IT | AT | Methodology | Effects on cellular respiration (reference, year) |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| 1 | Brazil/TcI | L6E9 | Cardiomyocytes from neonatal mice (C57BL/6) | 5:1 | 24h | 48hpi | Microarrays (Custom) | Repression of some OXPHOS related genes ( |
| 2 | Dm28c/TcI | Vero | Primary mouse cardiomyocytes from embryos. | 10:1 | 6h | 1 to 48hpi | Microarrays (Affymetrix) | No significant changes of some OXPHOS ( |
| 3 | Tulahuen/TcII | Rat Heart myoblast | Primary human cardiomyocytes (PromoCell) | 10:1 | 0 | 15min to 2hpi | Microarrays (Affymetrix) | No significant differences in pathways related to OXPHOS ( |
| 4 | Dm28c/TcI | Vero | Primary human cardiomyocytes (CelProgen) | 10:1 | 2h | 0, 3, 6, 12hpi | Microarrays (Agilent) | Up-regulation of OXPHOS related genes ( |
|
| ||||||||
| 5 | Sylvio/TcI | C2C12 | Male mice hearts(C3H/HeN) | 106/mice | NA | 3, 37, 110dpi | Microarrays (Clontech) | Down-regulation of OXPHOS related genes in cardiac tissue ( |
| 6 | NA | NA | Myocardial tissues from CCC or DCM patients | NA | NA | NA | Microarrays (Affymetrix) | Up-regulation of OXPHOS related genes in CCC patients ( |
| 7 | Brazil/TcI Y/TcII | ND | Male mice heart (CD-1) | 104/mice | NA | 30 to 180dpi | Microarrays (Custom) | Repression of some OXPHOS related genes at the chronic stage ( |
| 8 | Col1.7G2/ TcI JG/TcII | SWISS mice | Male mice heart (BALB/c) | 50/Mice | NA | 15dpi | Sequencing (Illumina) | Down-regulation of OXPHOS related genes when using the JG strain ( |
|
| ||||||||
| 9 | Sylvio/TcI | C2C12 | Cardiomyocytes (HL-1 and primary rat cardiomyocytes) | 5:1 | 3h | 48hpi | Histochemical staining | Decrease activities of complex I and III in HL-1 infected cardiomyocytes ( |
| 10 | Tulahuen/TcII Y/TcII | LLCMK2 | Normal human dermal fibroblasts | 50:1 | 1h | 48hpi | Seahorse | OCR increase in infected human fibroblast ( |
| 11 | Sylvio/TcI | C2C12 | Human THP-1 macrophages | 3:1 | 0 | 3 and 18hpi | Seahorse | OCR increase in infected human Macrophages ( |
| 12 | Dm28c/TcI | Vero | Primary human cardiomyocytes (CelProgen) | 10:1 | 2h | 6, 17, 24hhpi | Seahorse | Up-regulation of OXPHOS related genes and OCR increase ( |
| 14 | CLBr/TcVI | Vero | Primary mouse cardiomyocytes (BALB/c) | 5:1 | 0 | 24hpi | Seahorse | OCR decrease in infected mouse cardiomyocytes ( |
|
| ||||||||
| 15 | Sylvio/TcI | C2C12 | Cardiac mitochondria from male mice (C3H/HeN) | 104/mice | NA | 3-10dpi 14-40dpi >110dpi | Histochemical staining | Inhibition of the respiratory chain complexes (CI-CV)I n the myocardium of infected mice ( |
| 16 | Sylvio/TcI | NA | 6-8-week-old male C3H/HeN mice. (heart, stomach, skeletal muscle, colon) | 104/mice | NA | 20-35dpi 158-180dpi | Measure of antioxidant/oxidant status and mitochondrial function | Oxidative damage and mitochondria decay in acute infection in al tissues, and in heart and stomach in chronic infection, ( |
| 17 | ND | NA | Myocardium homogenates from CCC patients | NA | NA | NA | Western blot | Decrease in components of the creatine kinase system and ATP synthase complex from CCC patients ( |
| 18 | ND | NA | Cardiac biopsies from CCC patients | NA | NA | NA | Western blot and immunohistochemistry | Decrease in protein levels of subunits of the respiratory complexes (CI and CIII) in chagasic hearts biopses ( |
The blue and orange color show whether the study found a decrease or an increase in transcriptomic (light color) and functional (dark color) respiration in T. cruzi infected cells, respectively. (PM, Parasite Propagation Model; MOI, Multiplicity of Infection; IT, interaction time; AT, Analyzed time; NA, Not Applicable; ND, No Data available, OXPHOS, Mitochondrial oxidative phosphorylation system; C2C12, mice myoblast cells; LLCMK2, Kidney cells from Macaca mulatta; Vero, Kidney cells from Cercopithecus aethiops; Seahorse, Seahorse extracellular flux analyzer).
Studies related to the host AKT/PI3K response to T. cruzi infection.
| Strain/DTU | PM | Infection model | MOI | IT | AT | Methodology | Effects on AKT/PI3K (reference, year) |
|---|---|---|---|---|---|---|---|
| Y/TcIII | Blood of swiss mice | Swiss Mouse peritoneal macrophages | 10:1 | 0 | 30min | Phosphoinositide determination and assay of PI3K activity |
|
| RA/TcVI | Vero | Human and murine macrophages, NIH3T3 fibroblasts, L6E9 | 10:1 | 2h | 24hpi | Measure of the percentage of infection with PI3K inhibitors |
|
| Tulahuen/TcII | A/J mice and L6E9 | Adipocytes from 3T3-L1 murine fibroblasts | 2:1 to 5:1 | 0 | 96hpi | Immunoblot | Increase expression of PI3K and AKT activation in infected adipocytes ( |
| Sylvio/TcI | ND | Human Schwann cells | 50:1 | 2-3h | 3-5dpi | Microarrays (Custom) |
|
| Tulahuen/TcII | LLCMK2 | HeLa | 5:1 | 2h | 18, 72hpi | Genome wide RNAi | AKT regulates intracellular |
| Dm28c/TcII | Vero | HeLa | 10:1 | 4h | 0, 3, 6hpi | Microarrays (Agilent) | Transcription upregulation of the PI3K/AKT pathway ( |
| Dm28c/TcI | Vero | Primary human cardiomyocytes | 10:1 | 2h | 0, 2, 4, 6,12hpi | Microarrays (Agilent)/Western Blot | Transcription upregulation of the PI3K/AKT pathway. Overexpression of the phospho-Akt protein 24hpi ( |
| Y/TcII | LLCMK2 | C57BL/6 6-8 weeks mice, Heart tissue from CCC patients. | 103/ mouse 3:1 THP1 | 0 |
| Microarrays (Agilent), Western blot | Transcription upregulation of the PI3Kγ pathway in CCC samples and hearts of infected mice. pAKT1 and pAKT2 were increased in the heart tissue from CCC patients. The PI3Kγ activation in myeloid cells was essential to restrict |
The orange color show those studies where an increase in transcriptomic (light color) and/or functional (dark color) activation of the PI3K/AKT pathway was reported. (PM, Propagation Model; MOI, Multiplicity of Infection; IT, interaction time; AT, analyzed time; ND, No Data available; LLCMK2, Kidney cells from Macaca mulatta; Vero, Kidney cells from Cercopithecus aethiops; L6E9, Myoblast from rat cells).